Post on 12-Jul-2018
OVOMET® Composition
• Ovomet® is an innovative product obtained fromremoving the eggshell and the membranethrough a patented and environmentally-friendlyprocess.
• Eggshell membrane is a natural protective barrierwhich contains many beneficial elements forhealth and wellness.
VIII. Sept-16
OVOMET® Composition
• OVOMET®’s Composition:
Hyaluronic Acid (4%)
Collagen (33-38%)
Glucosamine (2%)
Chondroitin sulfate (2%)
Keratin (1%)
Lysozyme (1%)
Other elements:
• More than 500 different proteins
Hyaluronic Acid
Collagen
Glucosamine
Chondroitin
Keratine
Lysozyme
Other elements
• Growth factor β
• Ovocalixin
• Ovocleidin
• Ovotransferrin
• Elastin
• Desmosine
• Isodesmosine
• Sulfur-bearing amino acids: Methionine, cysteine.
VIII. Sept-16
How does OVOMET® work?C
olla
gen
(33
-38
%) Mostly from type I;
which is needed by the vascular system, skin, tendons, ligaments, the joints’ cartilage and bones. It is synthesized to heal lesions.
Collagen type I is more absorbable and digestible than Collagen type II. Besides, it activates the synthesis of Hyaluronic Acid and endogen collagen in the cartilage and where it is necessary.
Hya
luro
nic
Aci
d(4
%) Very important for the skin
and joints’ cartilage. It is a “major player” in the skin wounds and damage recovery, and it is also important in the joints lubrication.
Several studies have proven that only the high weight Hyaluronic Acid molecules as the ones in Ovomet®(over 650kDa) is effective in joint and the skin health.
Ch
on
dro
itin
Su
lph
ate
(2%
) It is an effective protector of the cartilage, synovial membrane and sub chondral bone; the three main structures damaged by arthritis. Besides, it seems to stop and decrease some factors which produce the inflammatory processes.
Glu
cosa
min
e(2
%) It plays a main role in
the cartilage’s integrity maintenance. It activates the synthesis of collagen, endogen chondroitin sulphate and glucosamine precursors and reduces and stops the progression of the arthritis and osteoarthritis’ symptoms
Lyso
zym
e(1
%) It is an enzyme with
important antibacterial effects as well as a powerful activator of the immune system.
It’s essential to reactivate it after going under immunosuppressive treatments (for cancer or after an organ’s transplantation) and for modulating it in case of autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc…)
Other: more than 500 different proteins acting as physical and microbiological barrier.
• Keratine• Growth factor - β
• Ovocalixin• Ovocleidin
• Ovotransferrin• Elastin
• Desmosine• Isodesmosine
VIII. Sept-16
OVOMET® Synergy
• Ovomet® is more effective due to thesynergy of its compounds.
• There are several studies which provethat the components’ synergy it’s among5 and 6 times more effective than theeffects of the components themselves.
*GAGs: Hyaluronic acid, Keratin and Chondroitin sulfate**Other Components: Growth factor β, Ovocalixin, Ovocleidin, Ovotransferrin, Elastin, Desmosine and Isodesmosine
VIII. Sept-16
OVOMET® Synergy effect - Comparative analysis
References:
*Ruff et al. Clinical Rheumatology August 2009; 28 (8): 907-914.
**Garcia-Tabar et al. International Journal of Sport Nutrition and Exercise Metabolism 2016 (26) S1-S15.
**Garcia-Tabar et al. Archivos de Medicina del Deporte 2015; 32 (5): 314-334.
**Blasco JMI et al. Int. J. Clin. Rheumatol. (2016) 11(5), 077-081
***Walbroel et al. The nature network 2011.
****Schauss et al. Journal of Agricultural and Food Chemistry 2012; 60 (16):4096-4101.
A comparison between different chondroprotectors. The pain level using WOMAC is represented
50
60
70
80
90
100
0 days 28-35-30 days 60-70-50 days
100
81,4
68,0
100
76,4
62,0
100
72,9
57,3
Comparison: two commercial hydrolyzed collagens vs Ovomet®
Jointsol® 5g BioCell 2g Ovomet® 0.3g
0 días 28-35-30-días 60-70-50 días50
60
70
80
90
100
0 days 30 days 60-50 days
10096,1
85,2
100
72,9
57,3
Comparison: Commercial eggshell membrane vsOvomet®
Ovomet® 0.3gOther EggshellMembrane 0.5g
VIII. Sept-16
OVOMET® Synergy effect - Comparative Analysis
A comparison between different chondroprotectors. The pain level using WOMAC is represented
References:
*Lugo et al. Nutrition Journal (2016) 15:14.
**Garcia-Tabar et al. International Journal ofSport Nutrition and Exercise Metabolism2016 (26) S1-S15.
**Garcia-Tabar et al. Archivos de Medicinadel Deporte 2015; 32 (5): 314-334.
**Blasco JMI et al. Int. J. Clin. Rheumatol.(2016) 11(5), 077-08150
55
60
65
70
75
80
85
90
95
100
0 days 10 days 30 days 60-50 days 90 days 120 days 150 days 180 days
100
94,3
88,4
85,6
80,3
77,3
73,6
70,1
100
92
86,3
82,4
77,9
72,9
69,6
66,6
100
93,3
84,2
78,1
71,7
65,7
62,9
58,7
100
84,3
72,9
57,3
Comparison: placebo vs glucosamine+chondroitin vs native collagen vs Ovomet®
Placebo Gluc+Cond UC II® Ovomet®0 días 10 días 30 días 60-50 días 90 días 120 días 150 días 180 días
VIII. Sept-16
OVOMET ® 3 Benefits 1 Product
• Ovomet® shows 3 main benefits:
Anti-inflammatory Analgesic Joint regenerator
• It is specially effective in:
Helping in joint function. Strengthening joints. Reducing joint pain. Treating osteoarthritis and arthritis. Preventing joint lesions. It favours the activation and modulation
of the immune system.
VIII. Sept-16
DOSAGE
300 miligrams per day per person / 12 mg per Kg of pet per day
SHORT-TERM BENEFITS
Showing benefits from 7 to 10 days
NO NEED TO SUSPEND THE TREATMENT AND NO SIDE EFFECTS
Completely natural product; no contraindications described and it’s gluten-free
ABSENCE OF HEAVY METALS
Non-chemical, completely clean and Environmental-friendly process
OVOMET® Features
• Ovomet® most relevant features:VIII. Sept-16
WATER ACTIVITY
It is lower than 0.5% so its conservation is not affected
EXPIRATION DATE OF THE PRODUCT
24 months
PURITY
OVOMET® is over 95% membrane
OVOMET® Features
• Other biographical references of studies
Effects of Natural Eggshell Membrane (NEM) on Cytokine Production in Cultures of Peripheral Blood Mononuclear Cells Kathleen F. Benson and Gitte S. Jensen from NIS Labs,Klamath Falls, Oregon, USA. Kevin J. Ruff from ESM Technologies, LLC, Carthage, Missouri, USA
Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: a randomized, multicentre, double-blind, placebo-controlled clinical study. Kevin J.Ruff & Anne Winkler & Robert W. Jackson & Dale P. DeVore & Barry W. Ritz
Egg Membrane as a New Biological DressJun. 25,2002ing in Split-Thickness Skin Graft Donor Sites: A Preliminary Clinical Evaluation. Jui-Yung Yang,MD; Shiow-ShuhChuang,MD;Wen-Guei Yang,MD;Pei-Kwei Tsay, PhD Presented at the 3rd Asian-Pacific Burns Conference (APBC) in Taipei, Taiwan, April 1-5, 2000. From the Department ofPlastic and Reconstructive Surgery. Chang Gung Memorial Hospital, Taipei. Received:; Accepted: Now. 25, 2002
VIII. Sept-16
Eggnovo’s StudiesC
linic
stu
die
s• Osteoarthritic/arthritic diagnosed people:
• Study1*: January2015• Study2:** October2015
• Runners*: Study January 2015
• Crossfitters*: Study January 2015
• Clinical synovitis study: March 2016
• Histological study: December 2015
• Absorption study: March 2016
• Capsules: March 2015• Snacks: October 2015• Diet with placebo: February 2016• Snacks with placebo: February 2016
• Skin hair and nails: Study February 2015
• Dermal Study: biophysical parameters (hydration, pigmentation, elasticity) 2016
* Publications: - Garcia-Tabar et al. International Journal of Sport Nutrition and Exercise Metabolism 2016 (26) S1-S15.- Garcia-Tabar et al. Archivos de Medicina del Deporte 2015; 32 (5): 314-334.- Blasco JMI et al. Int. J. Clin. Rheumatol. (2016) 11(5), 077-081
VIII. Sept-16
Studies Eggnovo
• Osteoarthritic/arthritic diagnosed people:
• Study 1*: January 2015• Study 2*: October 2015
• Runners*: Study January 2015
• Crossfitters*: Study January 2015
* Publications:
- Garcia-Tabar et al. Eggshell membrane in the treatment of pain and stiffness associated with joint and connective tissue disorders. International Journal of Sport Nutrition and Exercise Metabolism 2016 (26) S1-S15.- Garcia-Tabar et al. Suplementación con membrana de cáscara de huevo para tratar el dolor y la rigidez articular. Archivos de Medicina del Deporte 2015; 32 (5): 314-334.
- Blasco JMI et al. The Effect of Daily Administration of 300 mg of Ovomet® for Treatment of Arthritis in Elderly Patients. Int. J. Clin. Rheumatol. (2016) 11(5), 077-081
VIII. Sept-16
Results
Osteoarthritic and arthritic diagnosed people
“Before the Ovomet® intake, I could not go downstairs in themorning because of my knees stiffness. Nowadays, I can do itwithout problems.”(Woman 63 years old. Osteoarthritic diagnosed.)
Testimonials
VIII. Sept-16
Results
Runners
RESUMEN ESTUDIO RUNNERS
“When I took part in Ovomet® clinical study, I was almost sureto give up my Triathlon due to the problems with the 21 kmsrace. After the treatment, I could participate and finish anIronman in México” (Men, 38 years old. Athlete.)
Testimonials
VIII. Sept-16
Results
Clinical study Los Manzanos Clinic in Logroño: Osteoarthritic patients
• Average age: 73.5 years-old.
• Medical reviews in days 0, 20 and 50 of treatment.
• Pain rate very acute at the beginning of the study
VIII. Sept-16
Results
Clinical study Los Manzanos Clinic in Logroño: Osteoarthritic patients
20,0
50,0
70,0
0
20
40
60
80
20 30 50
Perc
enta
ge o
f p
atie
nts
wit
nan
im
pro
vem
en
t o
f p
ain
eq
ual
or
mo
re t
han
2
0 %
Time (days)
Relative primary response of pain
60,0
80,0
95,0
0
20
40
60
80
100
20 30 50
Perc
enta
ge o
f p
atie
nts
wit
nan
im
pro
vem
ent
of
stif
fnes
s eq
ual
or
mo
re t
han
20
%
Time (days)
Relative primary response of stiffness
VIII. Sept-16
Experimental studies
• Clinical study synovitis. March 2016
• Histological study. December 2015.
• In vitro Absorption study. March 2016.
VIII. Sept-16
Experimental studies
SYNOVITISInflammation of thesynovial membrane
Variation of sinovial liquid Increase of the production Change in the composition
OSTEOARTHRITIC MODERATEPATIENTS
OSTEOARTHRITIC ACUTE
PATIENTSRUNNERS CROSSFITERS
INFLAMMATION, SWELLINGPainStiffnessFunction
DEGENERATION OF THE CARTILAGE
Lack of nutritionCatabolic metabolites
VIII. Sept-16
Experimental studies: synovitis
SYNOVITISSynovial membrane inflammation
Increase of the joint space
CARTILAGE DEGENERATION
Lack of nutritionCatabolic metabolites
Group of experimental animals: 40 dogs (30 ovomet® + 10 placebo)
Treated dogs with 15 mg ovomet® Kg-1 dog day-1
40 days of treatment
INFLAMMATIONPainStiffnessFunction
Flexion grade 10,3%
Muscular perimeter 7,8%
Pain 7,8%Inflammatory blood
markers 16%NO, TNF-α
Hip sonography
General improvement37,4%
Hip function 15,8%Before After
Joint Space48,8%
VIII. Sept-16
Experimental studies: histologic
In vivo arthrosis study UNILEON
% degeneratedcartilage
% cartilage loss % depth of cartilageloss
Degeneration score
23% 16% 33% 20%
Surgery to cause knee arthrosis. Knee histological preparations
16 rats (8 treated + 8 control)
Rats treated with 5 mg ovomet® Kg-1 rat day-1
18 weeks of treatment
VIII. Sept-16